Further information is available from the product SPC / data sheet. Telephone 0800 500 3171 • Email info@jurox.co.uk • Web www.jurox.co.uk or contact your local technical sales representative.

AceSedate® and Buprelieve® are trademarks of Jurox Pty Limited, Rutherford, NSW 2320, Australia.

AceSedate® Dosage Chart for Horses

AceSedate®: Acepromazine, now licensed for horses

RECOMMENDED DOSE RANGE

Weight of horse / foal (kg)

Lower Dose (ml) 0.03 mg/kg

Upper Dose (ml) 0.1 mg/kg

50 0.15 0.5

100 0.30 1.0

150 0.45 1.5

200 0.60 2.0

250 0.75 2.5

300 0.90 3.0

350 1.05 3.5

400 1.20 4.0

450 1.35 4.5

500 1.50 5.0

600 1.80 6.0

700 2.10 7.0

800 2.40 8.0

900 2.70 9.0

1000 3.00 10.0

It is recommended to select the lower end of the dose range where possible.For more information about AceSedate dosing protocols, please contact our Veterinary Technical Advisors on 0800 500 3171.

PREMEDICATION: ANXIOLYSIS: SEDATION

The table below shows the dose ranges that can be given via intramuscular OR SLOW intravenous injection

based on the weight of the horse in kg.

The equine range from Jurox

AceSedate® is the second product from Jurox Animal Health licensed to support anaesthesia, analgesia and sedation in horses.

Buprelieve® is a 0.3mg/ml solution for injection containing buprenorphine.

If you require more information on AceSedate® for horses, or any other matters relating to anaesthesia and analgesia, please contact us on 0800 5003171 and one of our Technical Advisors will be happy to help.

Telephone 0800 500 3171 • Email info@jurox.co.uk • Web www.jurox.co.uk or contact your local technical sales representative.

AceSedate® and Buprelieve® are trademarks of Jurox Pty Limited, Rutherford, NSW 2320, Australia.

Acesedate 10 mg/ml solution for injection for horses contains 10 mg/ml acepromazine.

INDICATIONS: Anaesthetic Premedication: Following acepromazine administration, the amount of anaesthetic necessary to induce anaesthesia is considerably reduced. This reduction is approximately one-third of a suitable induction agent. Tranquilisation: Acepromazine tranquilisation (ataraxy) involves a modification of temperament which is not associated with hypnosis, narcosis or marked sedation. This is achieved with low doses of acepromazine. At low doses, acepromazine reduces anxiety which is beneficial for use in horses prior to shoeing or transportation. Sedation: At higher dose rates acepromazine is an effective sedative, as an adjunct to, or replacement for, physical restraint e.g. dentistry, handling and shoeing. The relaxant effects aid examination of the penis in horses and the treatment of tetanus and choke.

CONTRAINDICATIONS: Do not administer to breeding stallions. Paralysis of the retractor penis muscle has been associated with the use of parenterally administered acepromazine in horses. Do not use this product in conjunction with organophosphates and/or procaine hydrochloride, as it may enhance activity and potential toxicity. Do not, in any circumstances, ride horses within the 36 hours following administration of the product.

ADVERSE REACTIONS: Acepromazine has caused paraphimosis, sometimes as a sequel to priapism. When extrusion of the penis occurs, the owner should be advised to inform his veterinary surgeon if retraction of the penis does not take place within 2 - 3 hours. Suitable treatments have been described in the veterinary literature e.g. manual compression during the period of general anaesthesia, penile support and manual compression, use of an Esmarch bandage. Accidental intracarotid injection in horses can produce clinical signs ranging from disorientation to convulsive seizures and death.

PRECAUTIONS: Special precautions for use in animals: Situations may arise where general anaesthesia is required in the 4 - 6 hours following use of the product. In such cases care should be taken to reduce the induction dose of other premedicants and anaesthetic agents, particularly parenteral barbiturates, so as to avoid potentiation and additive depressant effects. When administered to male horses (geldings or non-breeding stallions), use the lowest dose recommended to produce the required effect* Acepromazine is an adrenoceptor blocking drug and this causes hypotension and lowered packed cell volume (PCV). The product should therefore be administered with great caution, and at low dose rates only to debilitated horses and animals in states of hypovolaemia, anaemia and shock, or with cardiovascular disease. Rehydration should precede acepromazine administration. Special precautions to be taken by the person administering the veterinary medicinal product to animals: This product contains a potent sedative; care should be taken when handling and administering this product to avoid accidental self-exposure. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician but DO NOT DRIVE as sedation may occur. Symptomatic treatment may be required.

This product may cause irritation of skin and eyes. Avoid contact with skin and eyes. If accidental eye contact occurs, flush gently with fresh running water for 15 minutes and seek medical advice if any irritation persists. In the event of accidental skin contact, wash the contaminated area with large amounts of soap and water. Medical advice should be sought if irritation persists. Wash hands and exposed skin thoroughly after use.

Legal Category UK POM-V

* Do not administer to breeding stallions as paralysis of the retractor penis muscle has been reported following the use of acepromazine.

BUPRELIEVE 0.3 mg/ml solution for injection contains 0.3 mg/ml buprenorphine. Legal Category UK POM-V

Further information is available from the product SPC / data sheet.

References1. GM Johnston, JK Eastment, JLN Wood, PM Taylor. The confidential enquiry into perioperative equine fatalities (CEPEF): mortality results of Phases 1 and 2;

Veterinary Anaesthesia and Analgesia, 2002, 29, 159-170

Use medicines responsibly (www.noah.co.uk/responsible)